Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...
GlobalData on MSN2d
EMA gives OMPD to Actuate’s pancreatic cancer therapyActuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883 ...
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...
Actuate Therapeutics (ACTU) announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab ...
Actuate Therapeutics, Inc. announced promising results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for treating metastatic ...
Meet security experts, leaders, managers & thought leaders from Actuate. Read detailed professional profiles on these movers & shakers. Check out their insights and articles on important security ...
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback